Compare Stocks: AEON, IMMP, CELU, and MCRB

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AEON AEON Biopharma	$0.24 -5.5%	$0.35	$0.18 ▼ $1.45	$12.01M	0.65	1.05 million shs	758,607 shs
CELU Celularity	$1.68 -8.2%	$0.88	$0.56 ▼ $2.55	$48.63M	0.79	12.20 million shs	349,406 shs
IMMP Prima BioMed	$0.36 -0.1%	$0.40	$0.29 ▼ $3.53	$53.78M	2.21	110,333 shs	62,022 shs
MCRB Seres Therapeutics	$5.72 +1.4%	$5.48	$4.32 ▼ $29.98	$57.46M	0.21	65,065 shs	36,446 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AEON AEON Biopharma	0.00%	-23.36%	-14.91%	-66.63%	-70.27%
CELU Celularity	0.00%	+6.33%	+145.97%	+92.59%	-34.12%
IMMP Prima BioMed	0.00%	-4.23%	-2.72%	-3.11%	-77.61%
MCRB Seres Therapeutics	0.00%	+11.94%	+18.67%	-13.73%	-69.08%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AEON AEON Biopharma	$0.24 -5.5%	$0.35	$0.18 ▼ $1.45	$12.01M	0.65	1.05 million shs	758,607 shs
CELU Celularity	$1.68 -8.2%	$0.88	$0.56 ▼ $2.55	$48.63M	0.79	12.20 million shs	349,406 shs
IMMP Prima BioMed	$0.36 -0.1%	$0.40	$0.29 ▼ $3.53	$53.78M	2.21	110,333 shs	62,022 shs
MCRB Seres Therapeutics	$5.72 +1.4%	$5.48	$4.32 ▼ $29.98	$57.46M	0.21	65,065 shs	36,446 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AEON AEON Biopharma	0.00%	-23.36%	-14.91%	-66.63%	-70.27%
CELU Celularity	0.00%	+6.33%	+145.97%	+92.59%	-34.12%
IMMP Prima BioMed	0.00%	-4.23%	-2.72%	-3.11%	-77.61%
MCRB Seres Therapeutics	0.00%	+11.94%	+18.67%	-13.73%	-69.08%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AEON AEON Biopharma	2.75	Moderate Buy	$1.10	356.81% Upside
CELU Celularity	2.00	Hold	$6.00	257.14% Upside
IMMP Prima BioMed	2.00	Hold	$5.50	1,407.26% Upside
MCRB Seres Therapeutics	2.25	Hold	$17.00	197.20% Upside

Current Analyst Ratings Breakdown

Latest AEON, IMMP, CELU, and MCRB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/3/2026	MCRB Seres Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/27/2026	CELU Celularity	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/14/2026	AEON AEON Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$5.00 ➝ $1.20
8/11/2026	MCRB Seres Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/5/2026	CELU Celularity	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/30/2026	AEON AEON Biopharma	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$1.00
7/10/2026	IMMP Prima BioMed	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/6/2026	CELU Celularity	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/23/2026	MCRB Seres Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$12.00
6/23/2026	MCRB Seres Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
6/23/2026	MCRB Seres Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$12.00

(Data available from 9/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AEON AEON Biopharma	N/A	N/A	N/A	N/A	($4.12) per share	N/A
CELU Celularity	$26.55M	1.83	N/A	N/A	($1.32) per share	-1.27
IMMP Prima BioMed	$16.40M	3.28	N/A	N/A	$0.63 per share	0.58
MCRB Seres Therapeutics	$790K	72.77	$1.09 per share	5.26	$3.44 per share	1.66

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AEON AEON Biopharma	-$36.63M	-$4.42	1.34	N/A	N/A	N/A	N/A	-994.63%	11/13/2026 (Estimated)
CELU Celularity	-$91.72M	-$3.33	N/A	N/A	N/A	-345.45%	N/A	-77.94%	11/13/2026 (Estimated)
IMMP Prima BioMed	-$39.78M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MCRB Seres Therapeutics	$5.70M	-$2.43	N/A	N/A	N/A	-1,192.94%	-114.82%	-34.15%	11/4/2026 (Estimated)

Latest AEON, IMMP, CELU, and MCRB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/5/2026	Q2 2026	MCRB Seres Therapeutics	-$2.18	$0.47	+$2.65	$0.47	$0.18 million	$0.74 million
7/30/2026	Q4 2026	IMMP Prima BioMed	N/A	-$0.09	N/A	-$0.0850	N/A	$3.68 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AEON AEON Biopharma	N/A	N/A	N/A	N/A	N/A
CELU Celularity	N/A	N/A	N/A	N/A	N/A
IMMP Prima BioMed	N/A	N/A	N/A	N/A	N/A
MCRB Seres Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AEON AEON Biopharma	N/A	0.22	0.22
CELU Celularity	N/A	0.15	0.15
IMMP Prima BioMed	N/A	5.69	N/A
MCRB Seres Therapeutics	N/A	2.11	2.11

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AEON AEON Biopharma	22.78%
CELU Celularity	19.02%
IMMP Prima BioMed	2.32%
MCRB Seres Therapeutics	59.34%

Insider Ownership

Company	Insider Ownership
AEON AEON Biopharma	9.40%
CELU Celularity	17.30%
IMMP Prima BioMed	3.07%
MCRB Seres Therapeutics	5.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AEON AEON Biopharma	5	49.88 million	74.37 million	Not Optionable
CELU Celularity	220	28.95 million	23.94 million	Optionable
IMMP Prima BioMed	2,021	147.37 million	142.85 million	Optionable
MCRB Seres Therapeutics	330	10.05 million	9.52 million	Optionable

AEON, IMMP, CELU, and MCRB Headlines

Recent News About These Companies

Seres Therapeutics (NASDAQ:MCRB) Stock Crosses Above Fifty Day Moving Average - Here's Why

September 3 at 3:20 AM | americanbankingnews.com

Seres Therapeutics (NASDAQ:MCRB) Stock Price Crosses Above 50 Day Moving Average - Should You Sell?

September 3 at 3:19 AM | marketbeat.com

Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference

September 1, 2026 | globenewswire.com

Seres Therapeutics (NASDAQ:MCRB) Stock Price Passes Below Fifty Day Moving Average - Here's Why

August 26, 2026 | americanbankingnews.com

Canaccord Genuity Reaffirms Their Buy Rating on Seres Therapeutics (MCRB)

August 20, 2026 | theglobeandmail.com

Seres Therapeutics: Q2 Earnings Snapshot

August 5, 2026 | finance.yahoo.com

Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs

August 5, 2026 | finance.yahoo.com

Seres Therapeutics Streamlines Cambridge Operations with Lease Changes

August 4, 2026 | tipranks.com

Seres Therapeutics' SER-155 posts 80% response in cancer immunotherapy GI toxicity study

July 11, 2026 | msn.com

Why Seres Therapeutics, Inc.’s (MCRB) Stock Is Down 11.18%

July 8, 2026 | aaii.comA

Seres Therapeutics Shareholders Approve Directors and Executive Pay

July 8, 2026 | tipranks.com

Seres Therapeutics, Inc. (MCRB) Discusses Promising SER-155 Clinical Trial Results for Immune Checkpoint Inhibitor Related Andropilatis Transcript

July 8, 2026 | seekingalpha.com

Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That ...

July 8, 2026 | finance.yahoo.com

Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment

July 8, 2026 | globenewswire.com

Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of ...

June 25, 2026 | caledonianrecord.comC

Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres’ SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis

June 25, 2026 | uk.finance.yahoo.com

Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres' SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis

June 25, 2026 | globenewswire.com

We're A Little Worried About Seres Therapeutics' (NASDAQ:MCRB) Cash Burn Rate

June 13, 2026 | finance.yahoo.com

Seres Therapeutics Sets 2026 Annual Shareholder Meeting Date

June 9, 2026 | theglobeandmail.com

Seres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going Lease Costs and Extend Projected Operating Cash Runway Well Into the First Quarter of ...

June 5, 2026 | finance.yahoo.com

Seres Therapeutics Secures $25 Million from Nestlé Health Science and Reduces Facility Costs to Enhance Financial Position

June 5, 2026 | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

AEON, IMMP, CELU, and MCRB Company Descriptions

AEON Biopharma NASDAQ:AEON

$0.24 -0.01 (-5.46%)

As of 09/4/2026 04:00 PM Eastern

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.

Celularity NASDAQ:CELU

$1.68 -0.15 (-8.20%)

As of 09/4/2026 04:00 PM Eastern

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.

Prima BioMed NASDAQ:IMMP

$0.36 0.00 (-0.05%)

As of 09/4/2026 04:00 PM Eastern

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

Seres Therapeutics NASDAQ:MCRB

$5.72 +0.08 (+1.42%)

As of 09/4/2026 04:00 PM Eastern

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AEON, IMMP, CELU, and MCRB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AEON, IMMP, CELU, and MCRB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AEON, IMMP, CELU, and MCRB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AEON, IMMP, CELU, and MCRB Company Descriptions

AEON Biopharma NASDAQ:AEON

Celularity NASDAQ:CELU

Prima BioMed NASDAQ:IMMP

Seres Therapeutics NASDAQ:MCRB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AEON, IMMP, CELU, and MCRB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AEON, IMMP, CELU, and MCRB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AEON, IMMP, CELU, and MCRB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AEON, IMMP, CELU, and MCRB Company Descriptions

AEON Biopharma NASDAQ:AEON

Celularity NASDAQ:CELU

Prima BioMed NASDAQ:IMMP

Seres Therapeutics NASDAQ:MCRB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools